1. process development of peptide or protein APIs from microbial or human recombinant fermentation processes
2. formulation development of biological injectable
3. manufacturing capacities of biological APIs, lyophilized injectable, and prefilled syringe/

The company’s lead product, OBI‑858, is a novel 760 kDa botulinum toxin derived from Clostridium botulinum type A. OBI‑858 has successfully completed a Phase I clinical trial, demonstrating excellent safety, tolerability, and preliminary efficacy in reduc

TBMC will leverage existing resources to integrate intelligent and smart platform to establish various biopharmaceuticals manufacturing facility.